{"title":"Plasma proteome profiling reveals biomarkers of chemotherapy resistance in patients with advanced colorectal cancer","authors":"Jingxin Yang, Jin Chen, Luobin Zhang, Fangming Zhou, Xiaozhen Cui, Ruijun Tian, Ruilian Xu","doi":"10.1002/qub2.34","DOIUrl":null,"url":null,"abstract":"Colorectal cancer (CRC) is one of the most common cancers. Patients with advanced CRC can only rely on chemotherapy to improve outcomes. However, primary drug resistance frequently occurs and is difficult to predict. Changes in plasma protein composition have shown potential in clinical diagnosis. Thus, it is urgent to identify potential protein biomarkers for primary resistance to chemotherapy for patients with CRC. Automatic sample preparation and high‐throughput analysis were used to explore potential plasma protein biomarkers. Drug susceptibility testing of circulating tumor cells (CTCs) has been investigated, and the relationship between their values and protein expressions has been discussed. In addition, the differential proteins in different chemotherapy outcomes have been analyzed. Finally, the potential biomarkers have been detected via enzyme‐linked immunosorbent assay (ELISA). Plasma proteome of 60 CRC patients were profiled. The correlation between plasma protein levels and the results of drug susceptibility testing of CTCs was performed, and 85 proteins showed a significant positive or negative correlation with chemotherapy resistance. Forty‐four CRC patients were then divided into three groups according to their chemotherapy outcomes (objective response, stable disease, and progressive disease), and 37 differential proteins were found to be related to chemotherapy resistance. The overlapping proteins were further investigated in an additional group of 79 patients using ELISA. Protein levels of F5 and PROZ significantly increased in the progressive disease group compared to other outcome groups. Our study indicated that F5 and PROZ proteins could represent potential biomarkers of resistance to chemotherapy in advanced CRC patients.","PeriodicalId":45660,"journal":{"name":"Quantitative Biology","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Quantitative Biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/qub2.34","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Colorectal cancer (CRC) is one of the most common cancers. Patients with advanced CRC can only rely on chemotherapy to improve outcomes. However, primary drug resistance frequently occurs and is difficult to predict. Changes in plasma protein composition have shown potential in clinical diagnosis. Thus, it is urgent to identify potential protein biomarkers for primary resistance to chemotherapy for patients with CRC. Automatic sample preparation and high‐throughput analysis were used to explore potential plasma protein biomarkers. Drug susceptibility testing of circulating tumor cells (CTCs) has been investigated, and the relationship between their values and protein expressions has been discussed. In addition, the differential proteins in different chemotherapy outcomes have been analyzed. Finally, the potential biomarkers have been detected via enzyme‐linked immunosorbent assay (ELISA). Plasma proteome of 60 CRC patients were profiled. The correlation between plasma protein levels and the results of drug susceptibility testing of CTCs was performed, and 85 proteins showed a significant positive or negative correlation with chemotherapy resistance. Forty‐four CRC patients were then divided into three groups according to their chemotherapy outcomes (objective response, stable disease, and progressive disease), and 37 differential proteins were found to be related to chemotherapy resistance. The overlapping proteins were further investigated in an additional group of 79 patients using ELISA. Protein levels of F5 and PROZ significantly increased in the progressive disease group compared to other outcome groups. Our study indicated that F5 and PROZ proteins could represent potential biomarkers of resistance to chemotherapy in advanced CRC patients.
期刊介绍:
Quantitative Biology is an interdisciplinary journal that focuses on original research that uses quantitative approaches and technologies to analyze and integrate biological systems, construct and model engineered life systems, and gain a deeper understanding of the life sciences. It aims to provide a platform for not only the analysis but also the integration and construction of biological systems. It is a quarterly journal seeking to provide an inter- and multi-disciplinary forum for a broad blend of peer-reviewed academic papers in order to promote rapid communication and exchange between scientists in the East and the West. The content of Quantitative Biology will mainly focus on the two broad and related areas: ·bioinformatics and computational biology, which focuses on dealing with information technologies and computational methodologies that can efficiently and accurately manipulate –omics data and transform molecular information into biological knowledge. ·systems and synthetic biology, which focuses on complex interactions in biological systems and the emergent functional properties, and on the design and construction of new biological functions and systems. Its goal is to reflect the significant advances made in quantitatively investigating and modeling both natural and engineered life systems at the molecular and higher levels. The journal particularly encourages original papers that link novel theory with cutting-edge experiments, especially in the newly emerging and multi-disciplinary areas of research. The journal also welcomes high-quality reviews and perspective articles.